ARCT | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 10%

Liquidity 69%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.05%

1 Month

-9.64%

3 Months

-45.17%

6 Months

-47.49%

1 Year

-32.99%

2 Year

49.86%

Key data

Stock price

$21.14

P/E Ratio

-7.90

DAY RANGE

N/A - N/A

EPS

-$2.70

52 WEEK RANGE

$17.52 - $45.00

52 WEEK CHANGE

-$0.34

MARKET CAP

568.262 M

YIELD

N/A

SHARES OUTSTANDING

26.932 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/12/2024

BETA

1.78

PUBLIC FLOAT

AVERAGE 10 VOLUME

$283,020

AVERAGE 30 VOLUME

$385,092

Company detail

CEO:
Region: US
Website: arcturusrx.com
Employees: 184
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

ARCT - Arcturus Therapeutics Holdings Inc